Significant Contract Modifications ($10M+) — February 03, 2026

Two wins totaling $457M in gov construction (GSA LPOE + NIH lab) with $144M outlayed (32% progress) provide revenue through 2028.

GDIT ($197M CMS IT, 51% outlayed) and Emmes ($169M NIAID data center, 70% outlayed) show rapid progress in long-term contracts to 2027+.

ATI's $304M BARDA drug production has only 4% outlayed despite full obligation, indicating early-stage funding.

Firm-fixed price in 40% of contracts ($458M Hensel Phelps) exposes to construction cost overruns amid low initial outlays (avg. 10-32%).

Long durations to 2028 (all contracts) vulnerable to HHS/GSA budget shifts; cost-plus structures (60% of value) limit margins via audits.

Unexercised options ~$192M across ATI ($72M), GDIT ($2M), Emmes ($117M) could boost topline 17% on average.

HHS lab/infectious disease focus ($653M, 58% total) positions construction and data firms for follow-ons post-2026 completions.

80% of value ($902M) tied to HHS for labs, drug production, IT, and data services, with 3/4 showing 50%+ outlays.

Full obligations in Hensel Phelps awards ($458M to 2028) contrast low biotech outlays, highlighting infra stability.

{"entity"=>"Hensel Phelps Construction Co.", "reason"=>"$457M dual wins represent 40% of period value with proven execution.", "trigger"=>"outlays >50% or GSA/NIH follow-ons"}

{"entity"=>"HHS budget (NIAID/CMS/NIH/BARDA)", "reason"=>"Dominates 80% value; extensions/options hinge on funding continuity.", "trigger"=>"FY2027 appropriations or mod delays"}